LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
once-weekly weight-loss drug, retatrutide, in adults with type II diabetes (T2D) This study, called TRANSCEND-T2D-1, evaluated three doses (4 mg, 9 mg and 12 mg) of the drug for 40 weeks against placebo in adults with T2D and inadequate glycemic control with diet and exercise alone. Eli Lilly reported results using two approaches — an efficacy estimand, which reflects outcomes in patients who stayed on treatment throughout the study period and a treatment-regimen estimand, which incorporates data from patients who discontinued treatment. The study achieved its primary endpoint. Under the efficacy estimand, patients who took retatrutide achieved A1C reduction (a measure of blood sugar levels) by an average of 1.7% to 2% compared to 0.8% in the placebo group. Across the treatment-regimen estimand, patients receiving the drug reduced A1C by an average of 1.7% to 1.9%, versus 0.8% in the placebo group. For a key secondary goal, patients who took the drug lost up to 16.8% of their bo
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial [Yahoo! Finance]Yahoo! Finance
- Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concern [Yahoo! Finance]Yahoo! Finance
- RBC Capital Sees Eli Lilly's (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results [Yahoo! Finance]Yahoo! Finance
- Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? [Yahoo! Finance]Yahoo! Finance
- Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- 3/17/26 - Form 4
- LLY's page on the SEC website